Prescribing Imipramine

Why Imipramine Still Matters

Imipramine is where modern psychopharmacology begins. Introduced in the 1950s as the first mass-marketed antidepressant, it did more than treat depression: it taught the field how antidepressants work at all. When Julius Axelrod added imipramine and radioactive norepinephrine to neural tissue and found the drug blocked the amine from being taken back up into the nerve terminal, he did not just explain one molecule, he discovered the reuptake transporter and launched the entire monoamine era. Every SSRI and SNRI on your formulary is a descendant of what imipramine revealed. It was the original dual reuptake inhibitor, norepinephrine plus serotonin, decades before venlafaxine and duloxetine were marketed as though the idea were new.

So why write a practical guide for a drug most prescribers now skip past? Because imipramine is not obsolete, it is displaced. SSRIs replaced the tricyclics not because they work better for depression (in the aggregate, they do not; head-to-head, TCAs match modern antidepressants) but because they are easier: safer in overdose, no blood levels, no ECGs, no anticholinergic burden. That convenience is real and it is why SSRIs deserve first-line status. But convenience is not the same as superiority, and there are specific patients for whom imipramine and its cousins are genuinely the better drug, and are being denied it.

A word on where imipramine sits in the tricyclic family. It is a tertiary amine, which means it is more serotonergic, more anticholinergic, and less well tolerated than the secondary amines (nortriptyline, desipramine) that are, in fact, partly its own metabolites: desipramine is demethylated imipramine. For many patients where "a TCA" is indicated, nortriptyline is the more tolerable choice. Imipramine earns its place where its specific evidence base is strongest: panic disorder, IBS, melancholic depression, and pain.

Part 1: Indications: Who Is Imipramine For?

FDA-Approved Uses

• Depression (major depressive disorder)
• Childhood nocturnal enuresis (ages 6 and older)

Panic disorder, agoraphobia, and the pain and IBS uses discussed below are all off-label, but each is strongly evidence-based; they belong in the evidence-based section that follows rather than on the FDA-approved list. The pediatric enuresis indication, though on-label, is largely legacy use and outside the scope of a psychiatric prescribing guide.

The Evidence-Based Clinical Uses

Melancholic depression, imipramine's home turf

This is the single most important thing to know about the tricyclics: they outperform SSRIs in melancholic depression. When all depressions are lumped together, TCAs and modern antidepressants are roughly equivalent, but the melancholic subtype is where the tricyclics pull ahead. Recognize the phenotype: pervasive, near-total anhedonia; ruminating guilt; loss of appetite; early-morning awakening; and prominent psychomotor change (retardation or agitation). For these patients, reaching for an SSRI first may be doing them a disservice. This is imipramine's most underused indication in modern practice.

Panic disorder, the historic and enduring indication

Imipramine's efficacy in panic was discovered by Klein and Fink in 1962, in patients whose "atypical paroxysmal episodes" (what we now call panic attacks) responded to robust imipramine doses but not to chlorpromazine, a finding that essentially defined panic disorder as a distinct, drug-responsive entity. In the landmark JAMA 2000 trial (Barlow et al., n=312), imipramine and CBT each produced a ~70% response at three months, versus 40% for placebo. Imipramine works, and works well, for panic.

There is a crucial nuance, though. After discontinuation, CBT held its gains far better than imipramine did. In that trial, six-month post-discontinuation relapse was roughly 4% for CBT versus ~25% for imipramine. The likely mechanism is instructive: patients treated with medication become attuned to their internal state while medicated; when the drug stops, the unmedicated body feels different, which can trigger the very hypervigilance and interoceptive fear that drives panic. This shapes how you should counsel patients.

Counseling script for panic: "For panic disorder, you have options: CBT alone, an SSRI alone, or both together. Combining them may bring faster relief. But the durability is best when the skills are learned without leaning on a medication, so if we use imipramine to get you moving, the plan is to also build the CBT skills that keep you well after we stop."

Depression with comorbid chronic pain

Imipramine's benefits here are comparable to duloxetine and superior to SSRIs. The pain relief is at least partly independent of the antidepressant effect: tricyclics modulate serotonin and norepinephrine along the descending spinal pain pathway, which is why they relieve pain even at sub-antidepressant doses and in patients who aren't depressed. If your depressed patient also has neuropathic pain, fibromyalgia-type symptoms, or a chronic pain syndrome, imipramine treats both with one drug.

Neuropathic and chronic pain (with or without depression)

As a class, tricyclics are among the most effective drugs we have for neuropathic pain. Cochrane data put the NNT around 3, better than SSRIs and comparable to venlafaxine and duloxetine. Doses are typically lower than antidepressant doses (often 25 to 100 mg, frequently at bedtime to also help sleep).

Irritable bowel syndrome

Tricyclics, imipramine and amitriptyline specifically, are more effective than SSRIs for IBS, at doses similar to those used for depression. For the depressed or anxious patient with prominent IBS, this is a genuine two-for-one.

Agoraphobia

Effective, particularly when combined with in vivo (group) exposure therapy, an old but replicated finding (Zitrin & Klein).

Treatment-resistant depression (as a later-stage option)

Failing an adequate TCA trial is, in classic staging, a marker of treatment resistance, which means the TCA belongs in the algorithm, generally after SSRI/SNRI failure and before or alongside an MAOI. Serum-level monitoring makes it possible to confirm you actually gave an adequate trial.

PTSD-related nightmares and insomnia

Listed among effective agents for trauma-related nightmares; a sedating dose of 25 to 100 mg at bedtime can help both sleep and nightmares.

Post-ECT maintenance

Tricyclics are used to forestall depressive relapse after a course of ECT. (Note the best-studied regimen here is nortriptyline plus lithium, the classic gold standard, but the principle extends to the class.)

Where Imipramine Is Not the Right Tricyclic

• OCD: Clomipramine, not imipramine, is the tricyclic for OCD, it is far more serotonergic and beats imipramine head-to-head. Don't reach for imipramine here.
• Insomnia as a primary target: Doxepin (very low dose) is the antihistaminergic tricyclic built for sleep.
• Elderly / fall-prone / cognitively vulnerable patients needing a TCA: Nortriptyline (least anticholinergic, lowest orthostatic risk) is the safer secondary-amine choice.

Who Should Not Get Imipramine

• Bipolar disorder / bipolar depression without a mood stabilizer. Tricyclics rank near the top of all antidepressants for inducing mania and mixed states. Screen for bipolarity before prescribing, and never use imipramine as monotherapy in a bipolar patient.
• Borderline personality disorder with suicidality. The overdose lethality is dangerous in a high-impulsivity population, and TCAs may trigger aggression or disinhibition.
• Active, high suicide/overdose risk without a dispensing safeguard.
• Significant cardiac conduction disease (baseline QT prolongation, bundle branch block, recent MI, unstable arrhythmia).
• Uncontrolled narrow-angle glaucoma, clinically significant urinary retention/BPH, uncontrolled seizure disorder: the anticholinergic and seizure-threshold effects make these relative-to-strong contraindications.

Part 2: Before You Start: Workup and Candidacy

The Pre-Start Checklist

There is no mandatory battery of blood labs to start imipramine the way there is for lithium. Routine LFT monitoring is not required: hepatotoxicity is vanishingly rare (about 4 per 100,000 patient-years). The key gates are the heart, the bipolar screen, and the overdose-risk assessment.

Who Is a Poor Candidate

• Untreated bipolar disorder
• Significant cardiac conduction disease / recent MI / QT prolongation
• Active high suicide risk without a safe dispensing plan
• Elderly patient with falls, cognitive impairment, or heavy anticholinergic burden: use a secondary amine instead
• Narrow-angle glaucoma, significant urinary retention, uncontrolled seizures

Part 3: How to Start and Dose

The Governing Principle

"The treatment is long, the dose is low." Start low, titrate slowly (every 5 to 7 days), and expect weeks to months for full antidepressant effect. Slow titration is the single biggest determinant of whether your patient tolerates the drug long enough to benefit. Unlike SSRIs, where higher doses often don't add efficacy, dose increases genuinely matter for tricyclics; the drug is more effective at adequate doses/levels. So you titrate deliberately: slowly, but toward a real target.

Formulations

Imipramine is commercially available as hydrochloride tablets (10, 25, and 50 mg) and as pamoate capsules (75, 100, 125, and 150 mg). There is no commercially manufactured oral liquid in the US; an oral solution (for example, 5 mg/mL) exists only as a compounding-pharmacy preparation, which is worth arranging when fine titration or difficulty swallowing genuinely requires it. Otherwise, the fine, cautious titration that panic patients and sensitive individuals need is readily achieved by splitting the 10 mg tablets.

Starting Dose and Titration by Indication

• Panic disorder, start especially low. Imipramine can cause early stimulation/jitteriness that panic patients experience as a worsening of their anxiety and will quit over. Start at roughly half the usual starting increment (and some very sensitive patients need to begin even lower, which is where splitting the 10 mg tablet, or a compounded liquid, earns its place). Titrate up gradually. Typical effective range: ~40 to 150 mg/day, individualized.
• Depression (general): Titrate toward ~75 to 150 mg/day, raising every 5 to 7 days. In melancholic depression, dose to the serum level (below) rather than to a fixed milligram target.
• Neuropathic/chronic pain and PTSD nightmares/insomnia: Often lower, 25 to 100 mg, frequently at bedtime; some patients benefit at the lower end.
• Maximum: The PDR ceiling is 300 mg/day. In treatment-resistant cases, higher doses (reports up to ~600 mg/day) have been used, but only with serum-level and ECG monitoring; this is specialist territory, not routine practice.

Dose Timing

Imipramine is sedating (histaminergic effect), so bedtime dosing is usually appropriate: it turns the sedation into a benefit and blunts daytime side effects. This is also why low-dose imipramine can serve double duty for sleep and nightmares.

Serum Levels: One of Imipramine's Real Advantages

Imipramine is one of only three tricyclics (with nortriptyline and desipramine) that has a clinically meaningful, well-studied therapeutic serum level, almost no modern antidepressant gives you this. What is measured is imipramine plus its active metabolite desipramine (desmethylimipramine), combined. Draw it at steady state, five half-lives (about 5 to 6 days) after reaching the target dose or any dose change, timed 8 to 12 hours after the last dose. It is most validated in melancholic depression, the population in which most of the level research was done.

Why Bother With the Level?

• It confirms adherence and detects the ultra-rapid metabolizer who looks "treatment-resistant" but is actually subtherapeutic, and the ultra-slow metabolizer who is toxic on a modest dose. Metabolizer variability is enormous: clinicians describe patients supratherapeutic on 75 mg and subtherapeutic on 200 mg.
• It confirms you gave an adequate trial before labeling a patient a TCA non-responder.
• It is essential when combining with CYP-inhibiting drugs (see interactions): the level tells you whether an interaction has pushed the patient toward toxicity.

Part 4: Monitoring

Imipramine's monitoring is lighter than lithium's but has its own short checklist, centered on the heart and the serum level rather than the kidneys and thyroid.

Monitor more closely in the elderly, in anyone on an interacting medication, and in patients with cardiac history.

Part 5: Side Effects and How to Manage Them

The governing principle: most imipramine side effects are anticholinergic, cardiovascular, or sedating; most are dose-dependent; many anticholinergic effects fade over 2 to 4 weeks if the patient tolerates the titration; and if the burden is unacceptable, switching to a secondary amine (nortriptyline/desipramine) solves much of it. Manage aggressively and early: side effects, not lack of efficacy, are the usual reason patients quit.

Anticholinergic Effects (the Signature TCA Burden)

Imipramine is a tertiary amine and thus meaningfully anticholinergic, more than nortriptyline or desipramine, less than amitriptyline.

Cardiovascular

• Orthostatic hypotension and falls (alpha-adrenergic blockade): the major cardiovascular problem, especially in the elderly. Start low, titrate slowly, check orthostatic vitals, educate on slow position changes and hydration; prefer a secondary amine in fall-prone patients.
• Cardiac conduction / arrhythmia: the type 1 antiarrhythmic effect can prolong QT and slow conduction. This is the basis for baseline ECG screening and for the overdose danger. Avoid in significant conduction disease.

Sedation

Common (histaminergic). Often useful in depression with insomnia or anxiety: dose at bedtime. If excessive and interfering with daytime function, reduce the dose or switch to a less sedating secondary amine.

Weight Gain

Tricyclics are associated with weight gain; tertiary amines like imipramine carry somewhat more risk than the secondary amines. Manage with diet/activity counseling and by considering an agent switch if it threatens adherence.

Sexual Dysfunction

All TCAs affect sexual function. Tertiary amines (imipramine) tend toward greater overall sexual dysfunction; secondary amines are less likely to cause anorgasmia but more likely to cause erectile dysfunction. Manage with dose adjustment, timing, or switching.

Seizure Threshold

TCAs lower it. Relevant in patients with seizure history or TBI: use cautiously or avoid.

Hepatotoxicity

Extremely rare (~4 per 100,000 patient-years). No routine LFT monitoring required.

Part 6: Overdose and Toxicity

This is imipramine's most serious liability and the reason it sits behind the SSRIs. Know it cold.

The Core Danger

Tricyclics are among the most lethal antidepressants in overdose, via their type 1 antiarrhythmic (cardiac conduction) effects: QRS widening, arrhythmias, and cardiovascular collapse, compounded by anticholinergic delirium, seizures, and hypotension. The TCAs have a narrow therapeutic index, in the same conceptual category as lithium and carbamazepine: the gap between a therapeutic level and a dangerous one is not large. (For calibration on how dangerous the class can be: amitriptyline, the most toxic TCA, carries a morbidity index of 345/1,000 and mortality 3.8/1,000 in poison-center data, one of the two most dangerous of all antidepressants studied. Imipramine is a tertiary amine of the same dangerous class.)

The Practical Consequences

• This is fundamentally a dispensing problem you control at the point of prescribing. In any patient with suicide risk or impulsivity, limit the quantity dispensed (e.g., a week at a time), involve family in holding and administering the medication, and prefer safer agents first.
• Avoid entirely in high-impulsivity, high-lethality-risk populations without safeguards; this is a large part of why borderline personality disorder with suicidality is a contraindication.

Boxed Warning

Part 7: Drug Interactions

Because the therapeutic window is narrow, interactions that raise the imipramine level are the ones that matter most.

Drugs That Raise Imipramine Levels (Toxicity Risk), via CYP450 Inhibition

Imipramine is metabolized hepatically (CYP2D6, CYP2C19, CYP1A2, and others). Many drugs, especially other antidepressants, inhibit these enzymes and drive the level up.

• Potent CYP inhibitors among antidepressants: paroxetine, fluoxetine, fluvoxamine. These meaningfully raise TCA levels.
• Other inhibitors: cimetidine, quinidine, and others.
• Clinical rule: When combining imipramine with an SSRI/SNRI or other CYP inhibitor, start low, increase slowly, and check the serum level: draw a baseline, add the interacting drug, and recheck in ~2 weeks.

The TCA-Augmentation-of-SSRIs Strategy

Adding a tricyclic to an SSRI (a strategy since the 1980s) provides noradrenergic enhancement on top of serotonergic effect. The catch is exactly the interaction above: the SSRI inhibits CYP and raises the TCA level. Start low, go slow, and monitor the level. (Nortriptyline is the better-studied augmentation agent precisely because its serum-level window makes the interaction easy to track, worth considering over imipramine for this specific role.)

Serotonin Syndrome

Imipramine is serotonergic; combined with other serotonergic agents (SSRIs, SNRIs, MAOIs, and others) it carries serotonin syndrome risk. Start low, monitor for agitation, tremor, hyperthermia, and rigidity. Combination with an MAOI is classically dangerous and requires appropriate washout.

Other Interactions

• Sympathomimetics (pseudoephedrine and similar): risk of a hypertensive response with tricyclics.
• Alcohol / CNS depressants: additive sedation and CNS depression.
• Other anticholinergics / antihistamines: additive anticholinergic burden.

Part 8: Special Populations

Elderly

This is the population that demands the most caution, and often the one where imipramine is the wrong tricyclic.

• The stacked risks: orthostatic hypotension and falls, anticholinergic effects (confusion, constipation, urinary retention, blurred vision), and the anticholinergic-dementia association. In older patients these can present obliquely, as difficulty reading, dental problems, small-bowel obstruction, or a UTI from urinary retention.
• If a TCA is truly indicated in an older patient, prefer nortriptyline, the least anticholinergic, lowest-orthostatic-risk tricyclic. Reserve imipramine for cases where its specific evidence base outweighs the tolerability cost.
• Dosing: start low, go slow, get a baseline ECG (age >40), and use the serum level.
• For sleep specifically, low-dose trazodone (~25 mg) has largely replaced low-dose tertiary-amine tricyclics in the elderly because of the anticholinergic burden.

Pregnancy

Detailed pregnancy data were not part of the distilled source notes, so approach this from mainstream pharmacology: imipramine is one of the oldest antidepressants and has a long, relatively reassuring track record, but the decision is individualized and should weigh the risks of untreated depression against medication exposure, ideally with maternal-fetal medicine input. Practical points: pregnancy alters drug metabolism and volume of distribution, so serum-level monitoring is a genuine asset here; and neonates exposed near term can show transient withdrawal/anticholinergic effects, warranting coordination with pediatrics around delivery. Do not start or stop reflexively, decide case by case with specialist input.

Lactation

Not detailed in the source notes; requires individualized review against current lactation resources. If breastfeeding proceeds, coordinate with pediatrics and monitor the infant.

Renal and Hepatic Impairment

• Hepatic: imipramine is cleared hepatically, so significant liver disease impairs metabolism and raises levels: use caution, dose conservatively, and lean on serum-level monitoring. Severe liver disease is a relative contraindication.
• Renal: less of a direct concern than for renally cleared drugs, but caution and conservative dosing are prudent in significant impairment. (Specific renal-adjustment data were not detailed in the source notes.)

Children and Adolescents

• The class-wide boxed warning for suicidality in youth applies, with FDA concern about activation.
• For pediatric anxiety and panic, CBT is generally the preferred first approach. Tricyclics in children also raise cardiac-monitoring and seizure considerations. Detailed pediatric psychiatric dosing was not part of the source notes; this is specialist territory.

Part 9: Discontinuation

Two distinct issues govern stopping imipramine.

1. Cholinergic-rebound / discontinuation symptoms. Stopping a tricyclic abruptly can produce a discontinuation syndrome, classically cholinergic rebound (GI upset, malaise, sleep disturbance). As a class, TCAs are generally easier to discontinue than the short-half-life SNRIs (venlafaxine, duloxetine) and paroxetine, but an abrupt stop is still unwise. Taper gradually. Abrupt withdrawal has also been associated with withdrawal-emergent movement phenomena in some reports, another reason to come down slowly.
2. Relapse risk, especially in panic disorder. As covered in Part 1, this is where discontinuation planning is most consequential. Panic patients relapse substantially more after stopping imipramine than after CBT (~25% vs ~4% at six months in the JAMA 2000 data). The clinical implication is not "never stop" but "build durable, non-pharmacologic tools alongside the drug," so that when you taper, the patient has skills that outlast the medication.

How to stop: taper gradually rather than abruptly, watch for both discontinuation symptoms and symptom relapse, and have a plan to resume (or resume-plus-therapy) if the underlying disorder re-emerges.

Part 10: Imipramine vs the Alternatives

vs SSRIs (the Default First-Line)

SSRIs win on safety (overdose), tolerability (no anticholinergic load), and convenience (no ECG, no levels), which is why they are first-line for most patients. But imipramine matches or beats SSRIs where it counts for specific patients: superior in melancholic depression, superior for comorbid chronic pain, superior for IBS, and fully effective in panic. In aggregate depression, the two are equivalent; the SSRI advantage is tolerability and safety, not efficacy.

vs the Secondary Amines (Nortriptyline, Desipramine)

These are imipramine's own better-tolerated relatives, less anticholinergic, less orthostatic. For the elderly, the fall-prone, the cognitively vulnerable, and for SSRI augmentation, a secondary amine is usually the smarter tricyclic. Imipramine holds its ground where its specific data are strongest (panic, IBS, melancholic depression, pain) and where its serotonergic component is wanted.

vs Clomipramine

For OCD and, head-to-head, for panic disorder, clomipramine is the more serotonergic and more effective tricyclic. If OCD is the target, it's clomipramine, not imipramine.

vs SNRIs (Duloxetine, Venlafaxine)

Essentially a fair fight on efficacy for pain and depression, the SNRIs are, in effect, cleaner dual reuptake inhibitors doing what imipramine pioneered. TCAs are comparable to duloxetine for pain (NNT ~3 vs ~5 for duloxetine in diabetic neuropathy) but far more dangerous in overdose. When you want dual reuptake action with better safety, the SNRI is the modern choice; when you specifically want a level-guided tricyclic or the SNRI has failed, imipramine remains valid.

vs MAOIs

For atypical depression and for TCA-resistant depression, MAOIs can succeed where tricyclics fail; they sit further along the treatment-resistance staging.

vs CBT (in Panic)

Equal acute response (~70% each), but CBT produces far more durable remission. The best long-term strategy in panic often leads with, or firmly includes, CBT.

So Why Is Imipramine Underused?

The SSRI revolution, aggressive marketing of newer agents, the real overdose and anticholinergic liabilities, and the "nuisance factor" of ECGs and blood levels. None of these are reasons it doesn't work, they are reasons it isn't convenient. For the melancholic, panic, pain, and IBS patient, that distinction matters.

Mechanism: The Short Version

Imipramine is a tertiary-amine tricyclic that blocks reuptake of both norepinephrine and serotonin, the original dual reuptake inhibitor, its mechanism famously elucidated by Julius Axelrod's demonstration that the drug prevents norepinephrine from being taken back into the nerve terminal (the experiment that revealed the reuptake transporter itself). It is emphatically not an MAOI. Its principal metabolite, desipramine, is a secondary amine that is more selective for norepinephrine, which is why the therapeutic serum level measures imipramine plus desipramine together.

Beyond monoamine reuptake, imipramine's receptor promiscuity explains its side-effect profile: antimuscarinic (anticholinergic) activity drives dry mouth, constipation, retention, and cognitive effects; alpha-adrenergic blockade drives orthostatic hypotension; and H1-histamine antagonism drives sedation and weight gain. Its type 1 antiarrhythmic effect on cardiac sodium channels underlies both the ECG-screening requirement and the overdose lethality. Its action on descending serotonergic and noradrenergic spinal pain pathways explains why it relieves neuropathic pain independently of any effect on mood.

The Bedside Cheat Sheet